Humacyte Shares Drop 11% on Stock Offering; Dialysis Trial Shows 220 vs 129 Catheter-Free Days
HUMA•Humacyte shares plunged 11% after-hours on news of a proposed common stock offering to fund Symvess sales, ATEV dialysis approval filing and operations. Late-stage results in 80 dialysis patients showed ATEV provided 220 catheter-free days vs 129 for AV fistula, with infection rates at 6 vs 23 per 100 patient-years.
1. Proposed Stock Offering and Share Impact
Humacyte announced an underwritten public offering of common stock, triggering an 11% drop in after-hours trading. The company did not disclose the size or price of the offering, raising investor concerns about potential share dilution.
2. Positive Dialysis Trial Results
Early data from 80 dialysis patients in a late-stage study showed the ATEV graft delivered 220 catheter-free days over 12 months compared with 129 days for an AV fistula, a 91-day improvement. Infection rates were 6 per 100 patient-years versus 23, and no vessel ruptures occurred in either group.
3. Use of Proceeds and Approval Timeline
Proceeds will support commercial launch of FDA-approved Symvess, advance other research, and cover operations. Humacyte plans to file an FDA approval application for ATEV in adult dialysis patients later this year.
